GSK (NYSE:GSK) Updates FY 2024 Earnings Guidance

GSK (NYSE:GSK) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 1.710-1.740 for the period, compared to the consensus estimate of 4.060. The company issued revenue guidance of $40.9 billion-$41.7 billion, compared to the consensus revenue estimate of $41.5 billion.

GSK Trading Up 0.3 %

NYSE GSK opened at $36.87 on Friday. The firm has a market capitalization of $76.41 billion, a PE ratio of 23.94, a price-to-earnings-growth ratio of 1.23 and a beta of 0.65. The business’s 50-day moving average price is $40.66 and its two-hundred day moving average price is $41.02. The company has a current ratio of 0.82, a quick ratio of 0.54 and a debt-to-equity ratio of 0.99. GSK has a 12 month low of $33.67 and a 12 month high of $45.92.

GSK (NYSE:GSK) last released its earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. The business had revenue of $9.95 billion during the quarter, compared to the consensus estimate of $9.49 billion. GSK had a net margin of 7.97% and a return on equity of 51.23%. On average, analysts expect that GSK will post 4.08 EPS for the current year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be given a dividend of $0.3928 per share. The ex-dividend date is Friday, November 15th. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a dividend yield of 4.26%. GSK’s dividend payout ratio is 98.70%.

Analyst Ratings Changes

GSK has been the topic of several recent analyst reports. UBS Group lowered GSK from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Barclays upgraded shares of GSK to a “hold” rating in a research report on Tuesday, August 27th. Argus upgraded shares of GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday. Five equities research analysts have rated the stock with a hold rating, one has given a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $50.00.

Insider Activity at GSK

In other news, major shareholder Plc Gsk acquired 2,791,930 shares of GSK stock in a transaction on Friday, September 27th. The stock was acquired at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the transaction, the insider now owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.00% of the stock is owned by insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.